



Press Release

Bayer Diabetes Care partners with International Diabetes Federation to support “Unite for Diabetes Campaign”

Campaign Aims to Raise Awareness of Diabetes Worldwide and Gain Government Support for a United Nations Resolution on Diabetes

Leverkusen – Bayer Diabetes Care, a division of Bayer HealthCare LLC and a member of the Bayer Group (NYSE: BAY), announced it has partnered with the International Diabetes Federation (IDF) to help support IDF’s “Unite for Diabetes Campaign”. The goal of the campaign is to gain action from governments for a United Nations Resolution on diabetes - to raise awareness of this chronic disease and prompt decision-makers to take preventative actions against the growing health challenge.

New data from the IDF show that more than 230 million people, almost 6% of the world’s adult population, now live with diabetes. The number of people living with diabetes is expected to grow to 350 million in less than 20 years if action is not taken.

Diabetes is one of the major causes of premature death worldwide. Every ten seconds a person dies from diabetes-related causes. The death rates are predicted to rise by 25% over the next decade. According to the World Health Organization (WHO), the disease could reduce life expectancy globally for the first time in 200 years.

IDF predicts that by 2025 almost 80% of all diabetes cases will be in low- and middle-income countries. If nothing is done, diabetes will place severe economic, social and health burdens on the countries that can least afford it.

“Bayer is proud to be a corporate partner of the “Unite for Diabetes Campaign” and hopes to help raise awareness of the diabetes epidemic and encourage national

government investment in better diabetes care services,” said Sandra Peterson, President, Bayer Diabetes Care.

The goal is to secure a Resolution on or around World Diabetes Day – November 14, 2007.

About Bayer HealthCare AG

Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. Bayer HealthCare generated sales amounting to some 9.4 billion euros and employed 33.800 people worldwide in 2005.

The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals divisions. The new Pharmaceuticals division was established on January 1, 2006, and comprises the former Biological Products and Pharmaceutical divisions. Pharmaceuticals now has three business units: Hematology/Cardiology, Oncology and Primary Care.

Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating diseases.

Leverkusen, October 23, 2006

lz (2006-0552E)

Contact:

Dr. Gisela Lenz,

Tel.: +49 (0) 214 30 58030, Fax: +49 (0) 214 30 56723

E-Mail: gisela.lenz@bayerhealthcare.com

We are only one click away – our press service online:

www.viva.vita.bayerhealthcare.com

Forward-Looking Statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.